MTSI has added another 4.4% this week to close at $391.41 — now trading within touching distance of the analyst consensus target of $398, a gap that frames the next leg of the thesis neatly.
The stock's rise has been relentless since the May 7 earnings blowout, which delivered a 16% single-day move and a 24% five-day gain. That momentum continues to compound: MTSI is up roughly 10% on the month and has left most of its semiconductor peers behind on both timeframes. SITM, the closest correlated peer, gained just 1.1% this week. KLIC added 9.0% and MKSI 17.7%, but neither carries MTSI's year-to-date trajectory. The outlier was WOLF, up 26% on the week — a very different story driven by its own idiosyncratic newsflow rather than shared sector dynamics.
Options tell the same cautious story flagged last week, and it has not resolved. The put/call ratio is running at 0.56, still above 1.1 standard deviations above its 20-day average of 0.39. A month ago, the PCR was near 0.18 — practically no hedging at all. It has been climbing steadily since late May, even as the stock itself has kept grinding higher. That divergence — price up, put demand up — is the defining tension in MTSI's positioning right now. The PCR hasn't reached its 52-week high of 0.73, so this reads as selective hedging into the August 6 earnings date rather than outright fear. Short interest adds little signal: at 2.8% of the free float, it's low and drifting, down 7% over the past month. Borrow availability is extremely loose at over 2,600% of short interest, with costs at just 0.50%. There is no short-side pressure of any consequence here.
The Street is broadly constructive, and recent analyst moves have been aggressive enough to notice. After the May 7 quarter, Barclays raised its target from $265 to $400, then followed up on May 22 with a further lift to $450 — making it one of the most bullish voices on the name. Evercore ISI raised to $427, Needham to $400, and Truist to $375. The notable exception is JPMorgan, which lifted its target from $240 to $345 but held a Neutral rating — leaving it well below where the stock is now trading. That Neutral at $345 versus a $391 stock is a live tension: MTSI has already blown through JPMorgan's updated target, putting the firm in an uncomfortable spot heading into the next quarter. The bull case centres on MACOM's exposure to 5G infrastructure, satellite communications, and defense-related RF semiconductors, where demand has remained robust. Bears point to a P/E above 66 and an EV/EBITDA near 61 — multiples that leave little room for a guidance miss. The EPS momentum factor scores a solid 70 on the 90-day measure, suggesting the earnings revision trend remains positive, though the 12-month forward EPS growth rank sits at just 13 — the Street isn't modelling explosive future growth from here.
On ownership, the institutional picture has been tilting in. FMR (Fidelity) added 4.1 million shares to reach a 13.9% stake — the largest single holder by some margin. BlackRock added 1.0 million shares to reach 11.2%. Vanguard appears to have initiated a new position of 3.6 million shares in the most recent reporting period. Wellington added 532,000 shares. CEO Stephen Daly sold roughly 4,400 shares in a cluster of transactions on May 29, netting approximately $1.6 million — modest in scale and consistent with routine plan-based selling rather than a directional statement, given the stock was already deep into its post-earnings run.
With the stock now effectively at the consensus price target and the August 6 earnings date drawing closer, the question investors are grappling with is whether MTSI needs a fresh upward revision cycle to sustain momentum — or whether the current hedging behaviour reflects something more specific about what the next quarter needs to deliver.
See the live data behind this article on ORTEX.
Open MTSI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
